The United States has initiated a formal investigation into Germany’s pharmaceutical pricing framework, citing persistent underpayment for medicines as the European nation attempts to curb spiraling healthcare expenditures. U.S. Trade Representative Jamieson Greer characterized Berlin’s proposed reforms as a serious step backward, signaling that Washington views the German approach as a direct threat to American intellectual property and market access.
The probe arrives as the White House advances a broader trade strategy targeting imports from 60 economies with duties of up to 12.5%.
This new framework aims to bypass the Supreme Court’s recent invalidation of President Donald Trump’s sweeping global tariffs, establishing a fresh legal pathway to enforce trade leverage.
The administration has already moved to continue collecting previously imposed tariffs despite court rulings that deemed them legally questionable, marking a significant shift in how the U.S. enforces its trade agenda.
For European markets, the development introduces fresh uncertainty regarding transatlantic commercial relations.
Germany’s pharmaceutical sector, a cornerstone of the country’s industrial base, now faces the prospect of targeted U.S. duties or retaliatory measures.